This trial showed that trastuzumab deruxtecan also achieved a clinically significant tumor response in patients with HER2-mutant advanced non-squamous NSCLC whose disease had progressed following one or more previous systemic therapies (chemotherapy or immunotherapy with immune checkpoint inhibitors against PD-1/PD-L1) [33]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.